Antitumor agent-53 

Antitumor agent-53 is a potent antitumor agent. Antitumor agent-53 induces cell cycle arrest at the G2/M phase. Antitumor agent-53 inhibits the PI3K/AKT pathway to induce the apoptosis of HGC-27 cells. Antitumor agent-53 has the potential for the research of gastrointestinal tumors^[1].

Antitumor agent-53 (compound 6f) (0, 0.22, 0.67, 2, 6, 18 µM; 72 h) shows anti-proliferation activity with IC₅₀s of 3.10, 0.37, 4.01, >18, 7.87, 9.11 µM for HGC-27, HT-29, HepG-2, A549, MCF7, GES-1 cells^[1].
Antitumor agent-53 (0.15, 0.3, 0.6 µM) shows anti-proliferative activity in HGC-27 and HT-29 cells with a dose-dependent manner^[1].
Antitumor agent-53 (100, 200 µM) shows a certain inhibitory activity against Topo I at 200 μM^[1].
Antitumor agent-53 (0.1, 0.3, 0.9 μM; 24 h) induces cell cycle arrest at the G2/M phase in HGC-27, HT-29 cells^[1].
Antitumor agent-53 (0.1, 0.3, 0.9, 2.7 μM; 24 h) induces the apoptosis of HGC-27 and HT-29 cells in a concentration-dependent manner^[1].
Antitumor agent-53 (0.15, 0.3, 0.6 μM; 24 h) inhibits the migration and invasion of HGC-27 cells in a concentration-dependent manner^[1].
Antitumor agent-53 (0.1, 0.3, 0.9 μM; 24 h) suppresses the PI3K/AKT pathway to induce the apoptosis of HGC-27 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

383.42

C₂₄H₁₈FN₃O

2757145-67-6

O=C1C2=C(N(C3C4=C(C5=CC=CC=C5N4)CCN13)C6=CC=CC(F)=C6)C=CC=C2

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Hao X, et al. Design, synthesis and bioactivity evaluation of novel N-phenyl-substituted evodiamine derivatives as potent anti-tumor agents. Bioorg Med Chem. 2021; 55:116595.  [Content Brief]